Oxford Genome Sciences (OGeS) has adopted an ambitious strategy to establish itself as a major player in the field of biological medicines in oncology. The company discovers and develops targeted antibody medicines with its partners Medarex, Biosite and Amgen to develop innovative & cost effective medicines to address large unmet patient needs. OGeS also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities. OGeS owns what is currently the largest database of disease-associated proteins in the world, OGAP^®, the Oxford Genome Anatomy Project, providing the opportunity to apply this approach to other diseases. Contained within OGAP^® is also the world's largest cancer protein database which has revealed a large number of novel clinically relevant cancer drug targets and diagnostics.